CLAIMS

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:



(I)

wherein:

A^1 is an optionally substituted aryl;

R^1 is an optionally substituted cycloalkyl;

R^2 and R^3 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted $C_{1\text{-}6}$ alkyl and an optionally substituted $C_{1\text{-}6}$ haloalkyl; or R^2 and R^3 together with the carbon to which R^2 and R^3 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;

R^4 and R^5 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted $C_{1\text{-}6}$ alkyl and an optionally substituted $C_{1\text{-}6}$ haloalkyl; or R^4 and R^5 together with the carbon to which R^4 and R^5 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;

R^6, R^7, R^8 and R^9 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted haloalkyl, an optionally substituted mono-substituted amine, and an optionally substituted di-substituted amine;

R^{10} is hydrogen, halogen, an optionally substituted alkyl, or an optionally substituted cycloalkyl;

R^{11} is hydrogen or an optionally substituted C_{1-6} alkyl; and

R^{12} is hydrogen or C_{1-3} alkyl.

2. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{11} is hydrogen.

3. The compound of any one of Claims 1 to 2, or a pharmaceutically acceptable salt thereof, wherein A^1 is an optionally substituted phenyl.

4. The compound of Claim 3, or a pharmaceutically acceptable salt thereof, wherein A^1 is a substituted phenyl.

5. The compound of Claim 4, or a pharmaceutically acceptable salt thereof, wherein A^1 is a 3,5-difluorophenyl.

6. The compound of Claim 3, or a pharmaceutically acceptable salt thereof, wherein A^1 is an unsubstituted phenyl.

7. The compound of any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R^1 is an optionally substituted cycloalkyl selected from the group consisting of unsubstituted cyclobutyl, unsubstituted difluorocyclobutyl, unsubstituted cyclopentyl and unsubstituted bicyclopentyl.

8. The compound of Claim 7, or a pharmaceutically acceptable salt thereof, wherein R^1 is an unsubstituted bicyclopentyl.

9. The compound of Claim 8, or a pharmaceutically acceptable salt thereof, wherein R^1 is an unsubstituted bicyclo[1.1.1]pentyl

10. The compound of any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R^1 is a substituted cycloalkyl.

11. The compound of any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R^2 is selected from the group consisting of hydrogen, methyl, fluoromethyl and difluoromethyl.

12. The compound of any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein any one or more of each of R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 and R^{10} is hydrogen.

13. The compound of any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R^6 is hydroxy.

14. The compound of any one of Claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R^7 is selected from the group consisting of halogen, hydroxy, and unsubstituted alkoxy.

15. The compound of Claim 14, or a pharmaceutically acceptable salt thereof, wherein R^7 is fluoro or methoxy.

16. The compound of any one of Claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R^8 is hydroxy.

17. The compound of Claim 1 selected from the group consisting of:


,

,

,

,

, and

, or a pharmaceutically acceptable salt of any of the foregoing.

18. The compound of Claim 1 selected from the group consisting of:


, and

,

or a pharmaceutically acceptable salt of any of the foregoing.

19. The compound of Claim 1 selected from the group consisting of:



,


,


,


,


,


,


,


,


,


,


,

and 

, or a pharmaceutically acceptable salt of any of the foregoing.

20. The compound of Claim 1 selected from the group consisting of:



, and 

, or a pharmaceutically acceptable salt of any of the foregoing.

21. The compound of Claim 1 of the Formula 11A:



11A

or a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition comprising an effective amount of the compound of any one of any one of Claims 1 to 21, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

23. An in vitro method of inhibiting the growth of a cell, comprising

identifying a cell having an estrogen receptor alpha that mediates a growth characteristic of the cell; and

contacting the cell with an effective amount of the compound of any one of Claims 1 to 21, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 22.

24. Use of the compound of any one of Claims 1 to 21, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 22, in the manufacture of a medicament for the treatment of a cancer that is estrogen receptor alpha dependent and/or estrogen receptor alpha mediated.

25. The use of Claim 24, wherein the cancer is selected from the group consisting of a breast cancer and a gynecological cancer.

26. The use of Claim 24, wherein the cancer is selected from the group consisting of breast cancer, endometrial cancer, ovarian cancer, and cervical cancer.

27. The use of Claim 24, wherein the cancer is breast cancer.

28. The use of any one of Claims 24 to 27, wherein said medicament for the treatment of cancer is to be administered intravenously.

29. The use of any one of Claims 24 to 27, wherein said medicament for the treatment of cancer is to be administered orally.

30. The use of any one of Claims 24 to 27, wherein said medicament for the treatment of cancer is to be administered intramuscularly.

31. The use of any one of Claims 24 to 27, wherein said medicament for the treatment of cancer is to be administered subcutaneously.

32. The use of any one of Claims 24 to 27, wherein said medicament for the treatment of cancer is to be administered topically.

33. A compound selected from the group consisting of 

and 

.

34. A compound of the following Formula 11-4:



11-4.

35. A compound of the following Formula 11-5:



11-5.

36. A method of making a compound of Formula 11A:



11-A,

comprising:

reacting a compound of Formula 11-1 with benzaldehyde to form a compound of Formula 11-2:



11-1 **11-2**

;

reacting the compound of Formula 11-2 with tricyclo[1.1.1.0^{1,3}]pentane of Formula 11-3 to form a compound of Formula 11-4:



;

hydrogenating the compound of Formula 11-4 to form a compound of Formula 11-5:



;

reacting the compound of Formula 11-5 with (*E*)-methyl-3-(3,5-difluoro-4-formylphenyl) acrylate to form a compound of Formula 11-6:



; and

hydrolyzing the compound of Formula 11-6 to form the compound of Formula 11A.